HDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma

ABSTRACT: Purpose: The clinical use of MEK inhibitors in uveal melanoma is limited by the rapid acquisition of resistance. The current study has used unbiased multi-omics and drug screens to identify the pan-HDAC inhibitor panobinostat as an effective strategy to limit MEK inhibitor resistance.

ORGANISM(S): Homo sapiens

PROVIDER: GSE127948 | GEO | 2019/06/11

REPOSITORIES: GEO